The US Department of Jystice has blamed Walmart for helping to fuel America's opioid crisis.
In a claim, examiners said the retailer filled a huge number of sketchy solutions and "purposely" disregarding checking rules.
Walmart claims the claim is "filled with real mistakes".
The retailer added that it "imagines a legitimate hypothesis that unlawfully powers drug specialists to divide patients and their PCPs".
Walmart, the world's biggest retailer, works in excess of 5,000 drug stores at its stores across the US and for quite a long time has additionally gone about as a medication merchant.
As per the claim recorded on Tuesday, the organization constrained staff to fill solutions as quick as could be expected under the circumstances and retained data from drug specialists, gathered by its consistence unit, which demonstrated such requests didn't have legitimate clinical purposes.
Accordingly, Walmart said it had sent the Drug Enforcement Administration (DEA) a huge number of insightful leads, and obstructed great many faulty specialists from having their narcotic solutions filled at its drug stores.
Jeffrey Bossert Clark, acting right hand principal legal officer of the Branch of Equity's considerate division, said Walmart's activities "added to the pandemic of narcotic maltreatment all through the US".
"As one of the biggest drug store chains and discount drug merchants in the nation, Walmart had the obligation and the way to help forestall the redirection of remedy narcotics," he said.
"All things being equal, for quite a long time, it did the inverse - filling a large number of invalid remedies at its drug stores and neglecting to report dubious requests of narcotics and different medications set by those drug stores."
For instance, when drug specialists announced hazardous requests to the consistence unit, it didn't share data about the prescribers all the more generally, as per the claim.
Walmart likewise didn't react to worries from dispersion staff that they needed more an ideal opportunity to assess orders, it said.
This made a "damaged" discovery framework, as indicated by the claim, which said Walmart detailed only 204 "dubious requests" to specialists more than four years, out of an expected 37.5m shipments.
Examiners said Walmart "significantly profited" from its activities, evading the cost of making legitimate consistence techniques and benefitting from the additional business - sometimes from alleged "pill plant" prescribers who guided their patients to the company's stores.
The public authority is looking for monetary punishments for the supposed wrongdoing, which it said dated to 2013. It said the fines could add up to "billions of dollars".
Walmart uncovered in October that it had been compromised with such a suit and said the US was forcing "unfeasible prerequisites that are not found in any law".
In its reaction to the claim on Tuesday, Walmart said the equity division is "requesting drug specialists and drug stores re-think specialists" and is putting them "in a sticky situation with state well being controllers who state they are as of now going excessively far in declining to fill narcotic remedies".
In an emphatic articulation, Walmart added the claim "develops a lawful hypothesis that unlawfully powers drug specialists to separate patients and their PCPs, and is loaded with verifiable mistakes and singled out reports taken outside of any relevant connection to the issue at hand."
Walmart said it had sent the DEA a huge number of insightful leads, and obstructed great many flawed specialists from having their narcotic remedies filled at its drug stores.
Approximately 450,000 individuals have passed on from overdoses identified with solution painkillers and illicit medications since 1999.
The claim against Walmart is the most recent exertion by the Branch of Equity to react to the general well being emergency.
In October, it reported that Oxycontin-creator Purdue Pharma would pay more than $8bn and confess to empowering the stock of medications without real clinical reason.